Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Clinical trial NCT07480213 · RECRUITING

Trial details

NCT number: NCT07480213
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC)Relapsed/Refractory SCLC SCLC, Extensive Stage

Start date: 2026-02-02
Primary completion: 2027-02-14
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.